-
Something wrong with this record ?
Slow sulfide donor GYY4137 potentiates effect of paclitaxel on colorectal carcinoma cells
M. Kajsik, B. Chovancova, V. Liskova, P. Babula, O. Krizanova
Language English Country Netherlands
Document type Journal Article
- MeSH
- Adenosine Triphosphate pharmacology MeSH
- Apoptosis MeSH
- Colorectal Neoplasms * pathology MeSH
- Humans MeSH
- Morpholines MeSH
- Cell Line, Tumor MeSH
- Organothiophosphorus Compounds MeSH
- Paclitaxel pharmacology MeSH
- Hydrogen Sulfide * metabolism MeSH
- Sulfides pharmacology therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Although paclitaxel (PTX) is potent chemotherapeutic agent commonly used in variety of cancers, in colorectal carcinoma its usage is excluded because of low effectivity. Up to now, some experimental attempts were utilized to improve sensitivity of colorectal carcinoma to PTX. We used a slow sulfide donor GYY4137 to increase sensitivity of colorectal carcinoma cells to PTX. As a model of colorectal carcinoma, we utilized three different cell lines - HCT116, SW620 and DLD1. We compared IC50 for PTX and PTX/GYY4137, cell cycle, apoptosis, ATP levels and changes in intracellular pH. We observed significant decrease in IC50 levels in PTX/GYY4137 groups compared to PTX in all three cell lines. PTX arrested cell cycle in G2/M phase. Differences in S phase were observed in HCT116 and DLD1 cells treated with 20 nM PTX/GYY4137, but not in SW620 cell. GYY4137 increased early, but not late phase of apoptosis. This increase was not detected in non-cancer EAHy926 cells. Upregulation of IP3R1 suggested involvement of these receptors in PTX and/or GYY4137 induced apoptosis. We also observed partial ATP depletion and intracellular acidification in PTX treated groups. In PTX/GYY4137 groups of all three cell lines no ATP depletion was detectable and intracellular acidification was lower than in PTX treated groups. Slight differences in all measured parameters were determined among HCT116, SW620 and DLD1 cells, which is probably due to physiological variations in these cells. Taking together, sensitivity of PTX to colorectal carcinoma cell lines could be increased by slow sulfide donor GYY4137, probably through potentiation of apoptosis.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018459
- 003
- CZ-PrNML
- 005
- 20220804134800.0
- 007
- ta
- 008
- 220720s2022 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejphar.2022.174875 $2 doi
- 035 __
- $a (PubMed)35314158
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Kajsik, Marek $u Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia; Department of Chemistry, Faculty of Natural Sciences, University of Ss. Cyril and Methodius, Namestie J. Herdu 2, 917 01, Trnava, Slovakia
- 245 10
- $a Slow sulfide donor GYY4137 potentiates effect of paclitaxel on colorectal carcinoma cells / $c M. Kajsik, B. Chovancova, V. Liskova, P. Babula, O. Krizanova
- 520 9_
- $a Although paclitaxel (PTX) is potent chemotherapeutic agent commonly used in variety of cancers, in colorectal carcinoma its usage is excluded because of low effectivity. Up to now, some experimental attempts were utilized to improve sensitivity of colorectal carcinoma to PTX. We used a slow sulfide donor GYY4137 to increase sensitivity of colorectal carcinoma cells to PTX. As a model of colorectal carcinoma, we utilized three different cell lines - HCT116, SW620 and DLD1. We compared IC50 for PTX and PTX/GYY4137, cell cycle, apoptosis, ATP levels and changes in intracellular pH. We observed significant decrease in IC50 levels in PTX/GYY4137 groups compared to PTX in all three cell lines. PTX arrested cell cycle in G2/M phase. Differences in S phase were observed in HCT116 and DLD1 cells treated with 20 nM PTX/GYY4137, but not in SW620 cell. GYY4137 increased early, but not late phase of apoptosis. This increase was not detected in non-cancer EAHy926 cells. Upregulation of IP3R1 suggested involvement of these receptors in PTX and/or GYY4137 induced apoptosis. We also observed partial ATP depletion and intracellular acidification in PTX treated groups. In PTX/GYY4137 groups of all three cell lines no ATP depletion was detectable and intracellular acidification was lower than in PTX treated groups. Slight differences in all measured parameters were determined among HCT116, SW620 and DLD1 cells, which is probably due to physiological variations in these cells. Taking together, sensitivity of PTX to colorectal carcinoma cell lines could be increased by slow sulfide donor GYY4137, probably through potentiation of apoptosis.
- 650 _2
- $a adenosintrifosfát $x farmakologie $7 D000255
- 650 _2
- $a apoptóza $7 D017209
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 12
- $a kolorektální nádory $x patologie $7 D015179
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a sulfan $x metabolismus $7 D006862
- 650 _2
- $a morfoliny $7 D009025
- 650 _2
- $a organothiofosforové sloučeniny $7 D009946
- 650 _2
- $a paclitaxel $x farmakologie $7 D017239
- 650 _2
- $a sulfidy $x farmakologie $x terapeutické užití $7 D013440
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Chovancova, Barbora $u Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia
- 700 1_
- $a Liskova, Veronika $u Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia
- 700 1_
- $a Babula, Petr $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. Electronic address: babula@med.muni.cz
- 700 1_
- $a Krizanova, Olga $u Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05, Bratislava, Slovakia; Department of Chemistry, Faculty of Natural Sciences, University of Ss. Cyril and Methodius, Namestie J. Herdu 2, 917 01, Trnava, Slovakia; Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. Electronic address: olga.krizanova@savba.sk
- 773 0_
- $w MED00001641 $t European journal of pharmacology $x 1879-0712 $g Roč. 922, č. - (2022), s. 174875
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35314158 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134754 $b ABA008
- 999 __
- $a ok $b bmc $g 1822172 $s 1169702
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 922 $c - $d 174875 $e 20220318 $i 1879-0712 $m European journal of pharmacology $n Eur J Pharmacol $x MED00001641
- LZP __
- $a Pubmed-20220720